Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile high-dose sunitinib versus TAS-102 in refractory metastatic colorectal cancer
NL-OMON27160Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) comparing TAS-102 standard arm with High-dose intermittent sunitinib experimental arm (2 arms). Primary endpoint: Progression-free survival. Started Oct 2019; status: recruiting.
02
Drugs
sunitinibtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON27160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27160.